ArticleBMC research notes2025
Minority adolescents' HIV PrEP awareness and preferences in Alabama.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveIn the southern United States, adolescents are at elevated risk for HIV acquisition. In Alabama, school-based sexual health and HIV prevention education is strictly regulated and does not address the unique needs of sexual and gender minority (SGM) teenagers. To inform public health efforts, we assessed SGM adolescents' HIV prevention pre-exposure prophylaxis (PrEP) awareness and modality preferences by gender, race, and ethnicity.
resultsSurvey data were collected in 2023-2024 from SGM adolescents aged 14-17 years, lived in Alabama, with male sex assigned at birth (N = 206). Recruitment occurred online and in-person at a charter school. Data were analyzed using chi-squares and analysis of variance, controlling for age. Over half of respondents were sexually active, but only 26% had ever been tested for HIV. Half knew about PrEP. Of those with PrEP awareness, 41.9% were aware of daily pills; 32.3% of long-acting injectable PrEP. Pill-based PrEP was highly endorsed. Trans- and gender-non-conforming adolescents reported a greater preference for on-demand pill-based PrEP compared to men who have sex with men (p =.01). Non-Hispanics had a greater preference for a 6-month long-acting injectable option compared to Hispanic adolescents (p =.04). Findings suggest the need for HIV prevention interventions tailored to southern contexts and adolescent knowledge.
trial registrationNot Applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.